Background: Short stature is a major clinical feature of Turner syndrome (TS). Recombinant growth hormone (GH) therapy improves growth outcomes, although individual responses remain heterogeneous. Identifying early factors associated with growth response may help optimize treatment and long-term patient management.
Objective: To evaluate growth outcomes and identify early clinical and auxological factors associated with response to GH therapy in girls with Turner syndrome.
Methods: A single-center retrospective cohort study included 37 girls with cytogenetically confirmed TS who received recombinant GH therapy at a tertiary pediatric endocrinology center. Clinical, auxological, biochemical, cytogenetic, and treatment-related data were collected. Age at diagnosis, age at GH initiation, baseline height SDS, IGF-1 levels, treatment duration, absolute height gain, and near-adult height were analyzed. Near-adult height was defined as a growth velocity below 2 cm/year, calculated from two height measurements obtained approximately 12 months apart. Associations between baseline characteristics and growth outcomes were assessed.
Results: The mean age at diagnosis was 8.3 ± 3.2 years, and GH therapy was initiated at a mean age of 9.1 ± 2.8 years. Baseline height SDS was −3.12 ± 0.74, and the mean treatment duration was 5.6 ± 2.1 years. Mean near-adult height was 146.2 ± 6.8 cm, with a mean absolute height gain of 16.8 ± 5.9 cm during follow-up. Earlier initiation of GH therapy was significantly associated with greater height gain and higher near-adult height (p<0.01). Baseline height SDS positively correlated with near-adult height SDS (r=0.64, p<0.001). Thyroid disorders occurred in 24.3% (n=9) of patients, while congenital cardiac anomalies occurred in 18.9% (n=7).
Conclusions: Earlier initiation of GH therapy was significantly associated with more favorable growth outcomes in girls with Turner syndrome. Baseline auxological status also influenced attained height. These findings support early diagnosis, timely initiation of GH therapy, and multidisciplinary follow-up to optimize near-adult height.

